Company Overview - Dingdang Health (09886.HK) closed at HKD 0.99 per share, up 23.75% with a trading volume of 33.3 million shares and a turnover of HKD 32.05 million, showing a volatility of 27.5% [1] - Over the past month, Dingdang Health has seen a cumulative increase of 45.45%, and a year-to-date increase of 60%, outperforming the Hang Seng Index by 25.45% [2] Financial Performance - As of December 31, 2024, Dingdang Health reported total revenue of CNY 4.669 billion, a year-on-year decrease of 3.87% - The company recorded a net loss attributable to shareholders of CNY 376 million, a significant decline of 66.73% year-on-year - The gross profit margin stood at 32.95%, with a debt-to-asset ratio of 36.18% [2] Valuation and Industry Comparison - Currently, there are no institutional investment ratings for Dingdang Health - The average price-to-earnings (P/E) ratio for the pharmaceutical and biotechnology industry is -2.05x, with a median of 1.44x - Dingdang Health's P/E ratio is -2.6x, ranking 148th in the industry, compared to peers such as Jingxin Pharmaceutical (00858.HK) at 1.32x and Hengrui Medicine (00013.HK) at 6.01x [3] Industry Positioning - Dingdang Health is recognized as a pioneer in providing rapid digital healthcare services in China, focusing on an online-to-offline model for instant pharmaceutical retail and medical consultation - The company aims to innovate and reshape the healthcare industry in China through technological advancements and business model innovation, continuing to invest in innovation to create value for the pharmaceutical industry and society [3] Upcoming Events - The company is scheduled to disclose its interim report for the fiscal year 2025 on August 22, 2025 [4]

Core Insights - Colorectal cancer (CRC) is the second most common malignant tumor in China, with 517,100 new cases in 2022, accounting for 10.7% of all cancer cases, and 240,000 deaths, representing 9.3% of all cancer deaths [1][12] - The global colorectal cancer drug market is projected to grow from $16.9 billion in 2019 to $25.4 billion by 2024, indicating significant market potential [1][13] - The Chinese colorectal cancer drug market is expected to reach 24.21 billion yuan by 2024, with an 18.5% year-on-year growth [1][16] - The market is characterized by a competitive landscape with multiple companies across different tiers, including leading firms like Junshi Biosciences and others [1][18] Industry Overview - Colorectal cancer drugs include traditional chemotherapy, targeted therapies, and immunotherapies, which are crucial for extending patient survival [2] - The burden of colorectal cancer in China is significant, with over 80% of patients diagnosed at advanced stages, leading to high treatment demands [1][16] - The market is expected to continue growing, with projections of 37.3 billion yuan by 2027 and nearly 60 billion yuan by 2031 [1][20] Competitive Landscape - The colorectal cancer drug industry features a tiered structure: - First tier: Junshi Biosciences - Second tier: Maibao Pharmaceutical, Hutchison China MediTech - Third tier: JAKS Pharmaceuticals, Jinfang Pharmaceutical [1][18] - Over 10 innovative therapies have been approved globally for colorectal cancer treatment, with more in clinical trials [1][18] Future Trends - The market is expected to see a shift towards precision medicine, with targeted and immunotherapies becoming mainstream [1][22] - Domestic innovative pharmaceutical companies are rapidly emerging, enhancing their product lines through independent research and global collaborations [1][23] - Upgraded patient needs will drive innovations in service models, focusing on unmet clinical demands and improving treatment experiences [1][25]

Core Viewpoint - Hutchison China MediTech Limited (和黄医药) announced the completion of patient enrollment for the SANOVO Phase III study, which evaluates the combination therapy of ORPATHYS® (savolitinib) and TAGRISSO® (osimertinib) for first-line treatment of specific non-small cell lung cancer patients with EGFR mutations and MET overexpression [1] Group 1 - The last patient was enrolled on August 18, 2025, marking the completion of the SANOVO study's patient recruitment [1] - Topline results from the SANOVO study are expected to be announced in the second half of 2026, with plans to submit the findings to relevant academic conferences [1] - If the results are favorable, the company plans to submit a new indication application to the National Medical Products Administration of China [1] Group 2 - ORPATHYS® is a potent and highly selective oral MET tyrosine kinase inhibitor developed in collaboration with AstraZeneca and commercialized by AstraZeneca [1] - TAGRISSO® is an irreversible third-generation EGFR TKI [1]

Core Insights - The announcement from Hutchison China MediTech (和黄医药) indicates the completion of patient enrollment for the SANOVO Phase III study, which evaluates the combination therapy of Savolitinib (沃瑞沙) and Osimertinib (泰瑞沙) for specific non-small cell lung cancer patients with EGFR mutations and MET overexpression [1] Group 1 - The SANOVO study is a randomized, controlled clinical trial assessing the efficacy and safety of the combination therapy compared to the standard monotherapy of Osimertinib [1] - The primary endpoint of the study is progression-free survival (PFS) as assessed by investigators, with secondary endpoints including independent review committee-assessed PFS, overall survival (OS), objective response rate (ORR), duration of response (DoR), disease control rate (DCR), time to response (TTR), and safety [1] - Topline results from the SANOVO study are expected to be announced in the second half of 2026, followed by submission of results to relevant academic conferences [1] Group 2 - Savolitinib is a potent and highly selective oral MET tyrosine kinase inhibitor (TKI) co-developed by AstraZeneca and Hutchison China MediTech, while Osimertinib is an irreversible third-generation EGFR TKI [2]

Group 1 - The core viewpoint of the news is that Hutchison China MediTech has completed patient enrollment for the SANOVO Phase III study, which evaluates the combination therapy of savolitinib and osimertinib for specific non-small cell lung cancer patients with EGFR mutations and MET overexpression [1][2] - The SANOVO study is a randomized controlled trial assessing the efficacy and safety of the combination therapy compared to osimertinib monotherapy, which is the current standard treatment for these patients [1] - The primary endpoint of the study is progression-free survival (PFS), with secondary endpoints including overall survival (OS), objective response rate (ORR), duration of response (DoR), disease control rate (DCR), time to response (TTR), and safety [1] Group 2 - Topline results from the SANOVO study are expected to be announced in the second half of 2026, followed by submission of the results to appropriate academic conferences [2] - If the results are favorable, Hutchison China MediTech plans to submit a new indication application to the National Medical Products Administration of China [2] - Savolitinib is described as a potent and highly selective oral MET tyrosine kinase inhibitor developed jointly by AstraZeneca and Hutchison China MediTech, while osimertinib is characterized as an irreversible third-generation EGFR TKI [2]

Group 1 - The SANOVO Phase III study has completed patient enrollment for the combination therapy of savolitinib (ORPATHYS) and osimertinib (TAGRISSO) in treating specific non-small cell lung cancer patients with EGFR mutations and MET overexpression [1] - The study is a randomized, controlled trial assessing the efficacy and safety of the combination therapy compared to osimertinib monotherapy, which is the current standard treatment for these patients [1] - The primary endpoint of the study is progression-free survival (PFS), with secondary endpoints including overall survival (OS), objective response rate (ORR), duration of response (DoR), disease control rate (DCR), time to response (TTR), and safety [1] Group 2 - Topline results from the SANOVO study are expected to be announced in the second half of 2026, followed by submission of results to appropriate academic conferences [2] - If the results are favorable, the company plans to submit a new indication application to the National Medical Products Administration of China [2] - Savolitinib is a potent, highly selective oral MET tyrosine kinase inhibitor developed jointly by AstraZeneca and the company, while osimertinib is an irreversible third-generation EGFR TKI [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不 對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 HUTCHMED (China) Limited 和黃醫藥（中國）有限公司 和黃醫藥完成沃瑞沙® 和泰瑞沙® 聯合療法用於一線治療特定肺癌患者的 SANOVO中國III期研究患者入組 和黃醫藥（中國）有限公司（簡稱「和黃醫藥」或「HUTCHMED」）今日宣佈沃瑞沙®（ORPATHYS®，賽沃替尼/ savolitinib）和泰瑞沙®（TAGRISSO®，奧希替尼/ osimertinib）的聯合療法用於一線治療伴有表皮生長因子受體 （「EGFR」）突變及MET過表達的特定非小細胞肺癌患者的SANOVO中國III期研究已完成患者入組。該研究的最後一 名患者已於2025年8月18日完成入组。 該項III期研究是一項在伴有EGFR激活突變及MET過表達的未經過治療的局部晚期或轉移性非小細胞肺癌患者中開 展的盲法、隨機對照的臨床試驗。該研究將評估泰瑞沙® 與沃瑞沙® 聯合療法對比泰瑞沙® 單藥（當前此類患者的標準 ...

Group 1 - The company achieved revenue of $278 million in the first half of 2025, with oncology business revenue of $144 million, including $99 million from oncology products and $44 million from upfront payments, milestone payments, R&D investments, and other income [1] - The latest oncology business guidance for 2025 is revised to $270-350 million, down from the previous $350-450 million, primarily due to delayed milestone income from partners until 2026 and beyond, and the new drug application approval for Solipnib in China expected to be completed after 2025 [1] - Domestic competition has led to a decline in sales, while the expansion of product indications is expected to drive performance growth [1] Group 2 - The new generation ATTC technology platform has the potential to create a rich pipeline of candidate drugs covering a wide range of oncology indications, including precision therapies for specific disease subtypes [2] - The company plans to announce preclinical data at academic conferences this year, with multiple successful developments of ATTC molecules expected to bring collaboration and licensing opportunities in the future [2] - The company maintains a "recommended" rating, as core products continue to expand indications, which is expected to drive performance growth, and the ATTC platform is anticipated to inject new vitality into the pipeline [2]

Company Overview - Charoen Pokphand International (03839.HK) closed at HKD 7.6 per share, up 16.21% with a trading volume of 3.08 million shares and a turnover of HKD 22.33 million, showing a volatility of 18.2% [1] - Over the past month, Charoen Pokphand International has seen a cumulative increase of 23.4%, and a year-to-date increase of 338.93%, outperforming the Hang Seng Index by 25.51% [1] - As of June 30, 2025, the company reported total revenue of CNY 2.315 billion, a year-on-year increase of 199.44%, and a net profit attributable to shareholders of CNY 122 million, a year-on-year increase of 768.36% [1] Financial Metrics - The gross profit margin stands at 12.92%, and the debt-to-asset ratio is 36.48% [1] - The company has a price-to-earnings (P/E) ratio of 7.67, ranking 8th in its industry, while the average P/E ratio for the pharmaceutical and biotechnology sector is -1.3 [2] Industry Context - The pharmaceutical and biotechnology industry has a median P/E ratio of 1.52, with other companies in the sector showing varying P/E ratios: - Other Excellent Pharmaceuticals (00858.HK) at 1.41 - Kingsray Biotechnology (01548.HK) at 1.64 - Dongrui Pharmaceutical (02348.HK) at 3.23 - Jilin Changlong Pharmaceutical (08049.HK) at 5.98 - Hutchison China MediTech (00013.HK) at 6.17 [2] Company Background - Charoen Pokphand International is a Hong Kong-listed company involved in biochemical and industrial businesses, established as part of Charoen Pokphand Group since 1995, and is a leading producer of oxytetracycline globally [2] - The company is also a significant stakeholder in one of China's four major Caterpillar distributors, holding 50% of the equity [2] - Charoen Pokphand International has been listed on the Hong Kong Stock Exchange since July 2015 and is a subsidiary of Charoen Pokphand Foods Public Company Limited (CPF.TB), a leading global agribusiness company listed on the Stock Exchange of Thailand [2]

Investment Rating - The report maintains a "Buy" rating for Hutchison China MediTech Limited (0013.HK) [1][8]. Core Views - The company is expected to benefit from the continuous expansion of product indications and the promising future of the ATTC platform, which is anticipated to inject new vitality into its pipeline [7][8]. - The revenue guidance for the oncology business has been revised down to USD 270-350 million for 2025, primarily due to delays in milestone income from partners and the postponement of the new drug application approval for a key product in China [4][8]. Financial Summary - For the first half of 2025, the company achieved revenue of USD 278 million, with oncology business revenue of USD 144 million [4]. - The projected net profit for 2025-2027 has been adjusted to USD 448 million, USD 92 million, and USD 109 million respectively, reflecting a significant increase from previous forecasts [8]. - The company’s revenue is expected to decline by 24.8% in 2024, followed by a slight decrease of 3.0% in 2025, before recovering with growth rates of 14.1% and 11.1% in 2026 and 2027 respectively [6][10]. Product Development and Market Position - The ATTC platform is expected to create a rich pipeline of drug candidates targeting a wide range of tumor indications, with clinical development planned to begin by the end of 2025 [7]. - The company’s core product, Savolitinib, has received approval for a new lung cancer indication in China, which is expected to participate in national medical insurance negotiations by the end of the year [7]. Market Performance - The stock is currently priced at HKD 25.2, with a total market capitalization of HKD 199.74 billion [1]. - The company’s gross margin is projected to improve from 44.6% in 2024 to 50.0% by 2027, indicating a positive trend in profitability [6][10].